The in vitro evolution of BCG vaccines

Area of Science:

• Microbiology
• Genomics
• Vaccinology

Background:

• Bacillus Calmette-Géurin (BCG) vaccines are derived from Mycobacterium bovis and used globally for tuberculosis (TB) prevention.
• BCG strains have undergone independent evolution and attenuation over decades, leading to genetic variations.
• The RD1 region deletion is linked to BCG attenuation, with subsequent deletions potentially causing over-attenuation.

Purpose of the Study:

• To comprehensively analyze the genomic content and variation within different BCG vaccine strains.
• To compare the in vitro evolution of BCG strains with the in vivo evolution of clinical Mycobacterium tuberculosis isolates.
• To understand the implications of genomic differences on TB pathogenicity.

Main Methods:

• Genomic content of BCG strains was investigated using Affymetrix GeneChip technology.
• Comparison of BCG strain genomics with previously characterized clinical isolates of M. tuberculosis.
• Analysis of genomic deletions, particularly the RD1 region and subsequent variations.

Main Results:

• Affymetrix GeneChip analysis provided a detailed description of the total genomic variation in BCG strains.
• The study allowed for a comparative analysis of evolutionary trajectories between BCG vaccine strains and M. tuberculosis clinical isolates.
• Genomic differences were identified that may contribute to variations in vaccine efficacy and TB pathogenicity.

Conclusions:

• Genomic characterization of BCG strains reveals significant evolutionary divergence.
• Comparing in vitro (BCG) and in vivo (M. tuberculosis) evolution provides insights into TB pathogenesis.
• Understanding BCG genomic variation is crucial for optimizing TB vaccine strategies and addressing pathogenicity.